Impact of the use of biologics and their discontinuation on the gut microbiota of psoriasis patients

• Autores: Penas Steinhardt, Alberto
• Año de publicación: 2025
• Idioma: inglés
• Tipo de recurso: artículo
• Materia: ARTICULO; PSORIASIS; MICROBIOTA
• Institución: Fundación H. A. Barceló

Fil: Penas Steinhardt, Alberto. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina.
Fil: Increasing number of studies have shown that the imbalance of gut microbial populations or dysbiosis may be implicated in psoriasis pathogenesis 1 Psoriasis treatment can shift the abundance of specific taxa however the effect of treatment discontinuation on gut microbiota has not been investigated At the start of the COVID 19 pandemic in March 2020 it was unclear whether patients on biologics were at risk of complications from COVID 19 infection The decision to continue or stop treatment in a group of patients under secukinumab treatment was individualised and agreed with the patient According to Blauvelt et al the median time to loss of PASI 50 after secukinumab withdrawal was 28 weeks so patients were not at increased risk of relapse 2 The aim of this study was to investigate whether there were differences in gut microbiota of psoriasis patients treated with secukinumab (IL 17 A inhibitor compared to controls non treated moderate to severe psoriasis patients and psoriasis patients after 3 months of secukinumab discontinuation discontinuation group